Over-expression of Kv4.3 gene reverses cardiac remodeling and transient-outward K+ current (Ito) reduction via CaMKII inhibition in myocardial infarction

Biomed Pharmacother. 2020 Dec:132:110896. doi: 10.1016/j.biopha.2020.110896. Epub 2020 Nov 2.

Abstract

Objective: Previous study has shown that Kv4.3, a main coding subunit generating cardiac transient-outward K+ current (Ito), can inhibit Ca2+/calmodulin-dependent protein kinase II (CaMKII) activity. Based on these observations, we speculate that over-expression of Kv4.3 gene could reverse not only Ito reduction but also cardiac remodeling in the rat myocardial infarction (MI) model.

Methods and results: Healthy male Sprague-Dawley (SD) rats were used to establish MI model by ligation of left anterior descending coronary artery, and adenovirus integrated with Kv4.3 gene (AD-Kv4.3) was delivered in infarct border zone by intramyocardial injection. The hearts were harvested for histological analysis (HE or Masson trichrome staining), western blot or patch clamp 4 weeks after MI. Our data showed that the application of AD-Kv4.3 could reduce myocardial infarct size and fibrosis, and its cardioprotective effects were similar with medicine therapy (combination of metoprolol and captopril). Moreover, Kv4.3 over-expression significantly improved MI-induced cardiac dysfunction and enhanced Ito density while decreasing corrected QT (QTc) intervals and cardiac electrophysiological instability. Western blot showed that Kv4.3 transfection reduced CaMKII, PLB-17 and ryanodine receptor2 (RyR2 Ser2814) phosphorylation level, at same time increased SERCA2 expression dramatically.

Conclusion: Over-expression of Kv4.3 can not only attenuate cardiac electrophysiological instability and cardiac performance, but also reduce myocardial infarct area and cardiac fibrosis. Like traditional anti-remodeling therapy-angiotensin converting enzyme inhibitor (ACEI) combined with β-adrenergic receptor blocker, over-expression of Kv4.3 seems to be an effective and safe therapy for both structural and electrical remodeling induced by MI via CaMKII inhibition.

Keywords: CaMKII; Cardiac remodeling; Kv4.3; Myocardial infarction.

MeSH terms

  • Animals
  • Anti-Arrhythmia Agents / administration & dosage
  • Antihypertensive Agents / administration & dosage
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / antagonists & inhibitors*
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism*
  • Gene Expression
  • Male
  • Myocardial Infarction / metabolism*
  • Myocardial Infarction / prevention & control
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Shal Potassium Channels / biosynthesis*
  • Shal Potassium Channels / genetics
  • Ventricular Remodeling / drug effects
  • Ventricular Remodeling / physiology*

Substances

  • Anti-Arrhythmia Agents
  • Antihypertensive Agents
  • Shal Potassium Channels
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2